%0 Journal Article
%T Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies.
%A Wei Y
%A Zhong S
%A Yang H
%A Wang X
%A Lv B
%A Bian Y
%A Pei Y
%A Xu C
%A Zhao Q
%A Wu Y
%A Luo D
%A Wang F
%A Sun H
%A Chen Y
%J Eur J Med Chem
%V 272
%N 0
%D 2024 Jun 5
%M 38759454
%F 7.088
%R 10.1016/j.ejmech.2024.116496
%X Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the first and second motoneurons (MNs), associated with muscle weakness, paralysis and finally death. The exact etiology of the disease still remains unclear. Currently, efforts to develop novel ALS treatments which target specific pathomechanisms are being studied. The mechanisms of ALS pathogenesis involve multiple factors, such as protein aggregation, glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, apoptosis, inflammation etc. Unfortunately, to date, there are only two FDA-approved drugs for ALS, riluzole and edavarone, without curative treatment for ALS. Herein, we give an overview of the many pathways and review the recent discovery and preclinical characterization of neuroprotective compounds. Meanwhile, drug combination and other therapeutic approaches are also reviewed. In the last part, we analyze the reasons of clinical failure and propose perspective on the treatment of ALS in the future.